Leap TherapeuticsLPTX
About: Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Employees: 52
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
47% more capital invested
Capital invested by funds: $37.8M [Q3] → $55.6M (+$17.8M) [Q4]
19% more funds holding
Funds holding: 48 [Q3] → 57 (+9) [Q4]
11.99% more ownership
Funds ownership: 38.46% [Q3] → 50.46% (+11.99%) [Q4]
70% less call options, than puts
Call options by funds: $43K | Put options by funds: $142K
Research analyst outlook
We haven’t received any recent analyst ratings for LPTX.
Financial journalist opinion
Based on 5 articles about LPTX published over the past 30 days
